

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT2897380

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
UGUR SAHIN	10/02/2008
OZLEM TURECI	10/02/2008
DIRK USENER	10/06/2008
STEFAN FRITZ	10/07/2008
CHRISTOPH UHEREK	10/10/2008
GUNDA BRANDENBURG	10/01/2008
HARALD-GERHARD GEPPERT	10/05/2008
ANJA KRISTINA SCHRODER	10/20/2008
PHILIPPE THIEL	10/08/2008

RECEIVING PARTY DATA

Name:	GANYMED PHARMACEUTICALS AG
Street Address:	FREILIGRATHSTRASSE 12
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55131
Name:	JOHANNES GUTENBERG-UNIVERSITAT MAINZ
Street Address:	SAARSTRASSE 21
City:	MAINZ
State/Country:	GERMANY
Postal Code:	55122

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	13306545
Application Number:	13425538

CORRESPONDENCE DATA

Fax Number: (312)775-8100

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 312-775-8000

Email: mhmpo@mcandrews-ip.com

PATENT

Correspondent Name: MCANDREWS, HELD & MALLOY, LTD.
Address Line 1: 500 W. MADISON ST.
Address Line 2: 34TH FL.
Address Line 4: CHICAGO, ILLINOIS 60661

ATTORNEY DOCKET NUMBER: 19682US02 & 19682US03

NAME OF SUBMITTER: ANGELINE R. BABEL

SIGNATURE: /Angeline R. Babel/

DATE SIGNED: 06/13/2014

Total Attachments: 14

source=19682US01_ORIGINAL_Filed_Assignment#page1.tif
source=19682US01_ORIGINAL_Filed_Assignment#page2.tif
source=19682US01_ORIGINAL_Filed_Assignment#page3.tif
source=19682US01_ORIGINAL_Filed_Assignment#page4.tif
source=19682US01_ORIGINAL_Filed_Assignment#page5.tif
source=19682US01_ORIGINAL_Filed_Assignment#page6.tif
source=19682US01_ORIGINAL_Filed_Assignment#page7.tif
source=19682US01_ORIGINAL_Filed_Assignment#page8.tif
source=19682US01_ORIGINAL_Filed_Assignment#page9.tif
source=19682US01_Addendum_to_Assignment#page1.tif
source=19682US01_Addendum_to_Assignment#page2.tif
source=19682US01_Addendum_to_Assignment#page3.tif
source=19682US01_Addendum_to_Assignment#page4.tif
source=19682US01_Addendum_to_Assignment#page5.tif

ASSIGNMENT

Case No. 19682US01

U.S. Serial No. 12/094,530 .

Inventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, and Philippe Thiel

NOW, THEREFORE, in exchange for good and valuable considerations in hand paid, the receipt and sufficiency whereof are hereby acknowledged, the undersigned hereby assigns to Ganymed Pharmaceuticals AG, a German corporation, at Freiligrathstrasse 12, Mainz, Germany 55131, and Johannes Gutenberg-Universität Mainz, at Saarstrasse 21, Mainz, Germany 55122, their successors and assigns, the entire right, title and interest in the invention or improvements of the undersigned disclosed in a United States patent application entitled "Monoclonal Antibodies Against Claudin-18 for Treatment of Cancer" and identified as Case No. 19682US01 in the offices of McANDREWS, HELD & MALLOY, LTD., filed in the United States Patent and Trademark Office as Serial No. 12/094,530 as a national-stage entry of International Patent Application Serial No. PCT/EP2006/011302, filed on November 24, 2006, and in any and all other (provisional or non-provisional) applications, both United States and foreign based thereon that claim priority thereto, which the undersigned may file, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of the United States and foreign countries, which may be obtained on any of said applications, and in any continuation, continuation-in-part, divisional, reexamination, renewal, substitutions, reissue or extension of such applications or patents, and further assigns to said assignee the priority right provided by the International Convention, treaties or otherwise.

The undersigned hereby authorizes and requests the Commissioner of Patents and Trademarks to issue said Letters Patent to said assignee.

The undersigned hereby authorizes and requests the attorneys of record in said application to insert in this Assignment the filing date and serial number of said application when officially known.

The undersigned warrants to be the owner of the entire right, title and interest in said invention or improvements and to have the right to make this Assignment, and further warrant that there are no outstanding prior assignments, licenses, or other encumbrances on the interest herein assigned.


For said considerations, the undersigned hereby agrees, upon the request and at the expense of said assignee, its successors and assigns, to execute any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application, and any and all applications and other document for Letters Patent in

foreign countries on said invention or improvements, that said assignee, its successors or assigns may deem necessary or expedient, and for the said considerations the undersigned authorizes said assignee to apply for patents for said invention or improvements in its own name in such countries where such procedure is proper and further agrees, upon the request of said assignee, its successors and assigns, to cooperate to the best of the ability of the undersigned with said assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent, both United States and foreign, and vest all rights therein hereby conveyed in the assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been made.

The assignee also has the right to enforce patent rights to such Patents as fully and entirely as the same would have been held and enjoyed by the Assignor if this Assignment had not been made; together with all claims by Assignor for damages by reason of past infringement or for provisional rights and including the right to sue for, and collect the same for its own use and benefit, and for the use and benefit of its successors, assigns, and other legal representatives.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.

EXECUTED this 2 day of 10, 2008.



Ugur Sahin

EXECUTED this 02 day of 10, 2008.



Ozlem Tureci

EXECUTED this _____ day of _____, 200_____.

Dirk Usener

foreign countries on said invention or improvements, that said assignee, its successors or assigns may deem necessary or expedient, and for the said considerations the undersigned authorizes said assignee to apply for patents for said invention or improvements in its own name in such countries where such procedure is proper and further agrees, upon the request of said assignee, its successors and assigns, to cooperate to the best of the ability of the undersigned with said assignee, its successors and assigns, in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent, both United States and foreign, and vest all rights therein hereby conveyed in the assignee, its successors and assigns, whereby said Letters Patent will be held and enjoyed by the said assignee, its successors and assigns, to the full end of the term for which said Letters Patent will be granted, as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been made.

The assignee also has the right to enforce patent rights to such Patents as fully and entirely as the same would have been held and enjoyed by the Assignor if this Assignment had not been made; together with all claims by Assignor for damages by reason of past infringement or for provisional rights and including the right to sue for, and collect the same for its own use and benefit, and for the use and benefit of its successors, assigns, and other legal representatives.

This Assignment may be executed in one or more counterparts, all of which shall be considered one and the same Assignment. The signatures from each counterpart may be combined with a copy of the Assignment to constitute the entire Assignment.


EXECUTED this _____ day of _____, 200_____.

Ugur Sahin

EXECUTED this _____ day of _____, 200_____.


Özlem Türeçli

EXECUTED this 6 day of 10, 2008.



Dirk Usener

EXECUTED this 07th day of Oct., 2008.



Stefan Fritz

EXECUTED this _____ day of _____, 200_____.

Christoph Uherek

EXECUTED this _____ day of _____, 200_____.

Gunda Brandenburg

EXECUTED this _____ day of _____, 200_____.

Harald-Gerhard Geppert

EXECUTED this 07th day of Oct., 2008.

Anja Kristina Schröder


EXECUTED this _____ day of _____, 200_____.

Philippe Thiel

EXECUTED this _____ day of _____, 200_____.

Stefan Fritz

EXECUTED this 10th day of October
Sept, 2008.



Christoph Uherek

EXECUTED this _____ day of _____, 200_____.

Gunda Brandenburg

EXECUTED this _____ day of _____, 200_____.

Harald-Gerhard Geppert

EXECUTED this _____ day of _____, 200_____.

Anja Kristina Schröder

EXECUTED this _____ day of _____, 200_____.

Philippe Thiel


EXECUTED this _____ day of _____, 200__.

Stefan Fritz

EXECUTED this _____ day of _____, 200__.

Christoph Uherek

EXECUTED this 1st day of Oct, 2008.



Gunda Brandenburg

EXECUTED this _____ day of _____, 200__.

Harald-Gerhard Geppert

EXECUTED this _____ day of _____, 200__.

Anja Kristina Schröder

EXECUTED this _____ day of _____, 200__.

Philippe Thiel

EXECUTED this _____ day of _____, 200_____.

Stefan Fritz


EXECUTED this _____ day of _____, 200_____.

Christoph Uherek

EXECUTED this _____ day of _____, 200_____.

Gunda Brandenburg

EXECUTED this 5th day of Oct., 2008.



Herald-Gerhard Geppert

EXECUTED this _____ day of _____, 200_____.

Anja Kristina Schröder

EXECUTED this _____ day of _____, 200_____.

Philippe Thiel

EXECUTED this _____ day of _____, 200_____.

Stefan Fritz

EXECUTED this _____ day of _____, 200_____.

Christoph Uherek

EXECUTED this _____ day of _____, 200_____.

Gunda Brandenburg

EXECUTED this _____ day of _____, 200_____.

Harald-Gerhard Geppert

EXECUTED this 20th day of Oct., 2008.



Anja Kristina Schröder

EXECUTED this _____ day of _____, 200_____.

Philippe Thiel

EXECUTED this _____ day of _____, 200__.

Stefan Fritz

EXECUTED this _____ day of _____, 200__.

Christoph Uherek

EXECUTED this _____ day of _____, 200__.

Gunda Brandenburg


EXECUTED this _____ day of _____, 200__.

Harald-Gerhard Geppert

EXECUTED this _____ day of _____, 200__.

Anja Kristina Schröder

EXECUTED this 8th day of Oct, 2008.



Philippe Thiel

ADDENDUM TO PATENT ASSIGNMENTS

THIS AGREEMENT ("Agreement") is made by Ganymed Pharmaceuticals AG, a German corporation, having a place of business at Freiligrathstrasse 12, Mainz, Germany 55131, and Johannes Gutenberg-Universität Mainz having a place of business at Saarstrasse 21, Mainz, Germany 55122 (collectively "the Parties").

WHEREAS, the Parties have entered into certain cooperation agreements/treaties dated June 28, 2005 and December 30, 2008 (the "Cooperation Treaties"), pursuant to which the details of the relationship between the Parties are specified.

WHEREAS, certain inventors have assigned the entire right, title and interest in and to certain patent applications and the invention and improvements disclosed therein jointly to the Parties (the "Assignments"), including those set forth on Exhibit A.

NOW, THEREFORE, in consideration of the agreements and covenants contained in the Cooperation Treaties and in exchange for other good and valuable consideration in hand paid, the receipt, adequacy, and sufficiency of which are hereby acknowledged, and subject to the terms and conditions of the Cooperation Treaties:

The Parties hereby agree that nothing in the Assignments, express or implied, is intended or shall be construed to modify, expand, or limit in any way the terms of the Cooperation Treaties, including, but not limited to, Articles 2.3.1 - 2.3.8 of the Cooperation Treaty dated June 28, 2005 and Articles 2.3.1 - 2.3.9 of the Cooperation Treaty dated December 30, 2008. As to the relationship between the Parties, the terms of the Assignments shall be subject to the terms of the Cooperation Treaties. In the event of any conflict or inconsistency between the terms of the Cooperation Treaties and the terms of the Assignments, the terms of the Cooperation Treaties shall supersede and govern.


Subject to the terms of the Cooperation Treaties, the Parties each hereby mutually covenant and agree to reasonably cooperate to enable each to enjoy to the fullest extent permitted under the Cooperation Treaties, the right, title and interest in and to said inventions or improvements. Such reasonable cooperation shall include execution of any and all continuation, continuation-in-part, divisional, extension, renewal, and substitute applications for said invention or improvements, and any necessary oath, affidavit or declaration relating thereto, and any application for the reissue, reexamination or extension of any Letters Patent that may be granted upon said application. The Parties further hereby mutually covenant and agree to cooperate in any proceedings or transactions involving such applications or patents, including the preparation and execution of preliminary statements, giving and producing evidence, and performing any and all other acts necessary to obtain said Letters Patent in the United States, and vest all rights therein hereby conveyed jointly in the Parties, each of their successors and assigns.

This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective successors and assigns.

This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same Agreement. The signatures from each counterpart may be combined with a copy of the Agreement to constitute the entire Agreement.

[SIGNATURE PAGE FOLLOWS]

FOR:
Ganymed Pharmaceuticals AG

By: 
Name: Dr. Rainer Wessel // Dirk Sebastian
Title: Vorstandssprecher // Vorstand

WITNESSED by  this 19 day of May, 2010

WITNESSED by  this 19 day of May, 2010

FOR:
Johannes Gutenberg-Universität Mainz

By: _____
Name:
Title:

WITNESSED by _____ this _____ day of _____, 20__.

WITNESSED by _____ this _____ day of _____, 20__.


FOR:
Ganymed Pharmaceuticals AG

By: _____
Name:
Title:

WITNESSED by _____ this _____ day of _____, 20__.

WITNESSED by _____ this _____ day of _____, 20__.

FOR:
Johannes Gutenberg-Universität Mainz

By: 
Name: _____
Title: **Universitätsprofessor Dr. Georg Kraus
Präsident**

WITNESSED by W. Sille this 02 day of 06, 2010.
Dr. Wolfgang Sille

WITNESSED by J. Rebowick this 02 day of 06, 2010.
Juse Rebowick

Exhibit A

Attorney Docket Number	Application Number	Application Date	Title
18704US02	12/601488	27-May-08	MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER
19568US01	12/066399	06-Sep-06	IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS FOR DIAGNOSIS AND THERAPY
19682US01	12/094530	24-Nov-06	MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER
19698US01	12/096216	07-Dec-06	COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF CANCER
20471US01	12/420612	08-Apr-09	COMPOSITIONS AND METHODS FOR THERAPY AND DIAGNOSIS OF CANCER AND CANCER METASTASIS
20536US01	12/420627	08-Apr-09	AUTOANTIGENES FOR IMPROVED DIAGNOSIS, PROGNOSIS AND TREATMENT OF INFLAMMATORY NEUROLOGICAL DISEASES